Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant

Janak Adhikari, Bishal Gyawali, Priyadarshani Sharma, Vijaya R Bhatt

Research output: Contribution to journalReview article

Abstract

The risk of acute and chronic graft-versus-host disease (GVHD) with haploidentical transplant with post-transplant high-dose cyclophosphamide may be lower compared with matched unrelated donor transplant and largely similar to matched related donor transplant. The lower probability of GVHD with the haploidentical donor may result in a risk of nonrelapse mortality that is at least similar to or even lower than the matched donor. The incidence of relapse and survival are also largely similar to different donor types. Haploidentical transplant may be associated with slower engraftment. Given a lower risk of GVHD, haploidentical transplant has gained popularity. Additionally, the use of post-transplant high-dose cyclophosphamide has been extended to lower the risk of GVHD with matched donor and mismatched unrelated donor transplant.

Original languageEnglish (US)
Pages (from-to)935-944
Number of pages10
JournalFuture Oncology
Volume13
Issue number10
DOIs
Publication statusPublished - Apr 2017

    Fingerprint

Keywords

  • allogeneic hematopoietic cell transplantation
  • donor source
  • engraftment
  • graft-versus-host disease
  • haploidentical hematopoietic cell transplantation
  • infection
  • matched hematopoietic cell transplantation
  • nonrelapse mortality
  • relapse
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this